Biogen Idec/Elan Tysabri Guaranteed Coverage Under Medicare Part B

Biogen Idec/Elan's once-monthly I.V. formulation of the multiple sclerosis therapy Tysabri guarantees that the product will be covered under Medicare Part B

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet